French pharmaceutical producer Sanofi has announced plans to cooperate with the life sciences team at Google to improve care and outcomes for people with type 1 and type 2 diabetes.

Sanofi said the collaboration will pair its leadership in diabetes treatments and devices with Google’s expertise in analytics, miniaturized electronics and low-power chip design.

To improve diabetes care, the prospective partners want to develop new tools to bring together many of the previously “siloed” pieces of diabetes management and enable new kinds of interventions, the drugmaker added.

Plans include new health indicators such as blood glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.

The goal of the collaboration is to make it easier for patients to successfully manage their diabetes, reduce the risk of complications, improve outcomes and ultimately lower costs.

“As a global leader in diabetes care, we have both an obligation and a commitment to provide integrated solutions for people living with diabetes,” said Sanofi CEO Olivier Brandicourt.

Andy Conrad, CEO of the Google life sciences team, said his company believes that cooperating with Sanofi, a market leader in diabetes treatments, management of the disease can be made simpler and more convenient.

Pascale Witz, executive vice president of Sanofi, will lead the Global Diabetes and Cardiovascular Care business unit in the French company’s new organizational structure.